Public criticisms of pharma patents are “way overstated”, Kathi Vidal tells IAM

Public criticisms of pharma patents are “way overstated”, Kathi Vidal tells IAM

The USPTO director shares her thoughts on life sciences IP rights and ongoing collaboration with the FDA

Unlock unlimited access to all IAM content